Singapore markets closed

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.31-0.09 (-0.96%)
At close: 1:00PM EST
9.31 0.00 (0.00%)
After hours: 01:01PM EST
Currency in USD

Valuation measures

Market cap (intra-day) 52.25B
Enterprise value 31.70B
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/sales (ttm)221.34
Price/book (mrq)2.28
Enterprise value/revenue 3167.41
Enterprise value/EBITDA 7-8.65

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-44.88%
S&P500 52-week change 326.87%
52-week high 319.84
52-week low 38.93
50-day moving average 312.61
200-day moving average 314.28

Share statistics

Avg vol (3-month) 3470.1k
Avg vol (10-day) 3332.75k
Shares outstanding 5240.47M
Implied shares outstanding 6N/A
Float 8124.02M
% held by insiders 116.16%
% held by institutions 132.15%
Shares short (14 Nov 2021) 44.95M
Short ratio (14 Nov 2021) 421.82
Short % of float (14 Nov 2021) 43.14%
Short % of shares outstanding (14 Nov 2021) 42.06%
Shares short (prior month 14 Oct 2021) 44.77M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sep 2021


Profit margin 0.00%
Operating margin (ttm)-2,082.35%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)N/A

Income statement

Revenue (ttm)10.14M
Revenue per share (ttm)0.13
Quarterly revenue growth (yoy)157.50%
Gross profit (ttm)7.76M
EBITDA -200.64M
Net income avi to common (ttm)-205.37M
Diluted EPS (ttm)-2.59
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)618.92M
Total cash per share (mrq)2.57
Total debt (mrq)67.23M
Total debt/equity (mrq)6.82
Current ratio (mrq)10.65
Book value per share (mrq)4.11

Cash flow statement

Operating cash flow (ttm)-119.81M
Levered free cash flow (ttm)N/A